{{Rsnum
|rsid=9871556
|Chromosome=3
|position=168953945
|Orientation=plus
|GMAF=0.343
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 14.4 | 55.0 | 30.6
| HCB | 65.7 | 27.7 | 6.6
| JPT | 54.9 | 38.9 | 6.2
| YRI | 93.9 | 6.1 | 0.0
| ASW | 66.7 | 33.3 | 0.0
| CHB | 65.7 | 27.7 | 6.6
| CHD | 65.1 | 32.1 | 2.8
| GIH | 36.6 | 54.5 | 8.9
| LWK | 89.1 | 10.9 | 0.0
| MEX | 26.3 | 47.4 | 26.3
| MKK | 71.2 | 28.2 | 0.6
| TSI | 16.7 | 52.0 | 31.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs9871556
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.45, combined P value= 1.61E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470163
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9871556
|overall_frequency_n=88
|overall_frequency_d=128
|overall_frequency=0.6875
|n_genomes=47
|n_genomes_annotated=0
|n_haplomes=76
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}